Achieving success in a UK-EU clinical trial requires the implementation of effective strategies for the release of Investigational Medicinal Products (IMPs), demanding careful planning and strict adherence to regulatory standards. The management of IMPs in trials spanning multiple jurisdictions is intricate, with the MHRA and EMA holding pivotal positions. MIAS Pharma, dedicated to serving Ireland and the UK, offers specialised expertise through a unified resource for both EU and UK trial releases. This approach is characterised by a streamlined and cost-effective methodology, ensuring strict compliance with the essential elements of regulatory requirements.

 

  • Comprehensive Regulatory Understanding:
    • Gain an in-depth understanding of MHRA and EMA regulations.
    • Account for overlapping but distinct requirements.

 

  • Risk Assessment and Mitigation:
    • Develop a comprehensive risk assessment for IMP release.
    • Identify bottlenecks, delays, and compliance issues.
    • Create strategies to mitigate risks and ensure a smoother process.

 

  • Streamlining Documentation:
    • Prioritise documentation for regulatory compliance.
    • Streamline paperwork for MHRA and EMA.
    • Create harmonized documents to save time and resources.

 

  • Experienced Personnel:
    • Employ personnel experienced in MHRA and EMA regulations.
    • Leverage regulatory affairs experts.
    • Gain guidance on compliance and develop customized strategies.

 

  • Communication and Coordination:
    • Establish open and transparent communication.
    • Involve stakeholders like sponsors, CROs, and regulatory authorities.
    • Minimise misunderstandings and delays.

 

  • Harmonisation and Consistency:
    • Develop a unified approach to IMP release.
    • Create standard operating procedures meeting MHRA and EMA requirements.
    • Ensure consistency across all trial jurisdictions.

 

  • Real-time Updates:
    • Stay informed about evolving regulatory guidelines.
    • Continuously monitor and adapt IMP release strategies.
    • Maintain compliance in response to regulatory changes.

 

By focusing on these key elements, MIAS Pharma aims to provide a comprehensive and tailored solution for managing IMPs in UK-EU clinical trials, ultimately contributing to the success of the trials and the development of new and innovative medical treatments.

 

For any questions get in touch with us at info@miaspharma.com